0F8847C7-545C-4C3C-B3D0-0681C9480712
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 72.8646517739816
- age_years
- 32
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.540
- TGF_BETA_SIGNALING+0.527
- APOPTOSIS+0.429
- TNFA_SIGNALING_VIA_NFKB+0.426
- NOTCH_SIGNALING+0.406
- ADIPOGENESIS+0.400
- UV_RESPONSE_DN+0.400
- INTERFERON_GAMMA_RESPONSE+0.389
- INTERFERON_ALPHA_RESPONSE+0.386
- ALLOGRAFT_REJECTION+0.369
Top 10 suppressed
- KRAS_SIGNALING_DN-0.300
- PANCREAS_BETA_CELLS-0.271
- E2F_TARGETS-0.268
- G2M_CHECKPOINT-0.187
- SPERMATOGENESIS-0.181
- MYC_TARGETS_V2-0.061
- MYOGENESIS-0.045
- ANGIOGENESIS-0.034
- WNT_BETA_CATENIN_SIGNALING+0.058
- APICAL_SURFACE+0.061
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.945 |
| 2 | 6C8488D3-6826-4156-9BD9-A12D8F35B72B | — | — | 0.903 |
| 3 | 01B819BD-664B-4D9E-B60B-9D9E8305A626 | — | — | 0.899 |
| 4 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.899 |
| 5 | 31D3488A-212B-4818-8F09-EBF1E8B135AD | — | — | 0.897 |
| 6 | SRR934729 | — | — | 0.897 |
| 7 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.894 |
| 8 | BS_ZZMYDZJW | pilocytic astrocytoma | — | 0.893 |
| 9 | SRR934843 | — | — | 0.891 |
| 10 | 8C34CD93-1AC0-4920-9E72-439EED0CF85D | — | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.540 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.527 | Inavolisib | — uncovered |
| APOPTOSIS | 0.429 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.426 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.406 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.389 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.386 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.369 | Idelalisib | — uncovered |
| COMPLEMENT | 0.368 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.365 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.364 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.352 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.343 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.327 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.326 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.321 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |